Volume 33, Issue 1 (April 2022)                   Studies in Medical Sciences 2022, 33(1): 19-26 | Back to browse issues page

XML Persian Abstract Print

Obstetrics and Gynecology Specialist, Department of Obstetrics and Gynecology, Zanjan University of Medical Sciences, Zanjan, Iran (Corresponding Author) , lida.garrosi@gmail.com
Abstract:   (1291 Views)
Background & Aims: Despite the high prevalence and importance of uterine myoma, no specific etiology has been proven for it so far. The aim of this study was to investigate the factors associated with the incidence of uterine myoma in the women of reproductive age in Tehran, Iran, along 2014-2015 years.
Materials & Methods: In this case-control study, 160 women referred to the Gynecology Clinic of Valiasr Hospital in Tehran along 2014-2015 years were chosen to the study and randomly divided into case and control groups. A demographic information questionnaire and a checklist of factors related to myoma were used to collect data. Finally, the data were analyzed by descriptive statistics, chi-square, t-test, and multivariate logistic regression tests using SPSS16 software.
Results: The mean age of women participating in this study was 34.69±6.57 years. Based on the data of this study, age and number of menstrual days, serum vitamin D level, menarche age, systolic blood pressure, family history, history of taking hormonal contraceptives, curettage, pregnancy history, and hypertension were directly and the duration of the menstrual cycle and Menarche age were inversely related to uterine myoma (P-value <0.05).
Conclusion: Some factors related to the occurrence of myoma such as family history and menstrual characteristics are not intervenable. However, interventions such as weight loss, avoidance of hormonal contraceptives, vitamin D consumption, and control of blood pressure can reduce the possibility of myoma.
Full-Text [PDF 461 kb]   (576 Downloads)    
Type of Study: Research | Subject: زنان و زایمان

1. Drayers S.m., Catherino W.H. Prevalence, morbidity, and current medical management of uterin leiomyomas. Int J Gynecol Obstet 2015;131:117-22. [DOI:10.1016/j.ijgo.2015.04.051] [PMID]
2. Sharami S, Zahiri Z, Ghanaie M. Risk Factors of Uterine Leiomyoma in Women of Reproductive Ages. J Babol Univ Med Sci 2009;11(4):54-61. [Google Scholar]
3. Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and risk factors of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2018;46:3-11. [DOI:10.1016/j.bpobgyn.2017.09.004] [PMID]
4. Tinelli A, Vinciguerra M, Malvasi A, Andjić M, Babović I, Sparić R. Uterine fibroids and diet. Int J Environ Res Public Health 2021;18(3):1066. [DOI:10.3390/ijerph18031066] [PMID] [PMCID]
5. Hoffman PJ, Milliken DB, Gregg LC, Davis RR, Gregg JP. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 2004;82(3):639-49. [DOI:10.1016/j.fertnstert.2004.01.047] [PMID]
6. Hillard JA. Benign disease of female reproductive tract symptoms and sign.In:Berek JS.Novaks gynecology. 13thed, Philadelphia, Lippincott William & illkins.2002.pp:351-420.
7. Stewart EA. Uterine fibroids. Lancet 2001;357(9252):293-8. [DOI:10.1016/S0140-6736(00)03622-9] [PMID]
8. Flake GP. Anderen J. Dixon D. Etiology and Pathogenesis of Uterine Leiomyomas: A Review. Environ Health Perspect 2003;111(8):1037-54. [DOI:10.1289/ehp.5787] [PMID] [PMCID]
9. Baird DD. Dunson DB. Why is parity protective for uterine fibroids? Epidemiol J 2003;14(2):247-50. [DOI:10.1097/01.EDE.0000054360.61254.27] [PMID]
10. Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine fibroids: from menarche to menopause. Clin Obstet Gynecol 2016;59(1):2e24. [DOI:10.1097/GRF.0000000000000164] [PMID] [PMCID]
11. Wise LA. Palmer JR. Spiegelman D,et al. Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S.black women. Epidemiolog 2005;16(3):340-54. [DOI:10.1097/01.ede.0000158742.11877.99] [PMID] [PMCID]
12. Faersein E. Szklo M. Rosenshein N. Risk factorsfor uterine Leiomyoma: a practice-based-control study.I.African-American heritage, reproductive history, body size, and smoking. Am J Epidemiology 2001;153(1):1-10. [DOI:10.1093/aje/153.1.1] [PMID]
13. Lurie S, Piper I, Woliovitch I, Glezerman M. Age-related prevalence of sonographically confirmed uterine myomas. J Obstet Gynaecol 2005;25:42-4. [DOI:10.1080/01443610400024583] [PMID]
14. Lethaby A, Vollenhoven B. Fibroids (uterine myomatosis, leiomyomas). Am Fam Physician 2005;71:1753-6. [Google Scholar]
15. Velebil P, Wingo PA, Xia Z, Wilcox LS, Peterson HB. 1995. Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States. Obstet Gynecol 1995;86:764-9. [DOI:10.1016/0029-7844(95)00252-M] [PMID]
16. Ciavattini A, Delli Carpini G, Moriconi L, et al. The association between ultrasound-estimated visceral fat deposition and uterine fibroids: an observational study. Gynecol Endocrinol 2017;23:1e4. [Google Scholar]
17. Parazzini F, Negri E, La Vecchia C, Fedele L, Rabaiotti M, Luchini L. 1992. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 79:430-3. [DOI:10.1097/00006250-199203000-00021] [PMID]
18. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. 1998a. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril;70:432-9. [DOI:10.1016/S0015-0282(98)00208-8] [PMID]
19. Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study. Br J Obstet Gynaecol;996;103:909-14. [DOI:10.1111/j.1471-0528.1996.tb09911.x] [PMID]
20. Asghar Neia M, Faraji R, Mir Hagh Jou SN, Karimi M. Frequency of Uterine fibroids and related risk factors in women with hysterectomy. J Holistic Nurs Midwifery 2013;23(1):1-6. [Google Scholar]
21. Faersein E. Szklo M. Rosenshein N. Risk factors for uterine Leiomyoma: a practice-based-control study.I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiology 2001;153(1):1-10. [DOI:10.1093/aje/153.1.1] [PMID]
22. Arinkan SA, Serifoglu H. The possible association of uterine fibroid formation with copper intrauterine device use: a cross-sectional study. Clin Exper Obstetr Gynecol 2021;48(4):969-73. [DOI:10.31083/j.ceog4804153]
23. . Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996;2:295-306. [DOI:10.1093/humupd/2.4.295] [PMID]
24. Marino JL, Eskenazi B, Warner M, Samuels S, Vercellini P, Gavoni N, et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod 2004;19:2350-5. [DOI:10.1093/humrep/deh407] [PMID]
25. Baird DD, Hill MC, Schectman JM, Hollis BW. Vitamin d and the risk of uterine fibroids. Epidemiolog 2013;24(3):447-53. [DOI:10.1097/EDE.0b013e31828acca0] [PMID] [PMCID]
26. Ahmed AA, Deif OM, Al-Latif A, Saad S, Mohamed AM. Serum protein and prolactin in evaluation of uterine fibroids. Egy J Hospital Med 2019;76(3):3653-8. [DOI:10.21608/ejhm.2019.39903]
27. Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 2001;153(1):11-9. [DOI:10.1093/aje/153.1.11] [PMID]
28. Stewart EA, Borah BJ. Uterine fibroids and hypertension: Steps toward understanding the link. J Clin Endocrinol Metabolism 2021;106(2):e1039-41. [DOI:10.1210/clinem/dgaa829] [PMID]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.